Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Biotech’s balancing act amid Covid-19 delays
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Global Blood aims for sickle cell dominance
Global Blood punching above its weight in sickle cell as 2022 sales forecasts for voxelotor hit $529m in 2022.